R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian,Mario Sznol,David F. McDermott,Harriet M. Kluger,Richard D. Carvajal,William H. Sharfman,Julie R. Brahmer,Donald P. Lawrence,Michael B. Atkins,John D. Powderly,Philip D. Leming,Evan J. Lipson,Igor Puzanov,David Smith,Janis M. Taube,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Drew M. Pardoll,Jeffrey A. Sosman,F. Stephen Hodi +20 more
TL;DR: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation.
Journal ArticleDOI
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger,Leora Horn,Leena Gandhi,David R. Spigel,Scott J. Antonia,Naiyer A. Rizvi,John D. Powderly,Rebecca S. Heist,Richard D. Carvajal,David M. Jackman,Lecia V. Sequist,David Smith,Philip D. Leming,David P. Carbone,Mary Pinder-Schenck,Suzanne L. Topalian,F. Stephen Hodi,Jeffrey A. Sosman,Mario Sznol,David F. McDermott,Drew M. Pardoll,Vindira Sankar,Christoph Matthias Ahlers,Mark E. Salvati,Jon M. Wigginton,Matthew D. Hellmann,Georgia Kollia,Ashok Kumar Gupta,Julie R. Brahmer +28 more
TL;DR: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC, and overall survival, response durability, and long-term safety were reported.
Journal ArticleDOI
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat,Nelly G. Adel,Thu-Oanh Dang,Parisa Momtaz,Michael A. Postow,Margaret K. Callahan,Richard D. Carvajal,Mark A. Dickson,Sandra P. D'Angelo,Kaitlin M. Woo,Katherine S. Panageas,Jedd D. Wolchok,Paul B. Chapman +12 more
TL;DR: In the experience, approximately one-third of ipilimumab-treated patients required systemic corticosteroids, and almost one- third of those required further immune suppression with anti-TNFα therapy, which does not affect OS or TTF.
Journal ArticleDOI
KIT as a therapeutic target in metastatic melanoma
Richard D. Carvajal,Cristina R. Antonescu,Jedd D. Wolchok,Paul B. Chapman,Ruth-Ann Roman,Jerrold B. Teitcher,Katherine S. Panageas,Klaus J. Busam,Bartosz Chmielowski,Jose Lutzky,Anna C. Pavlick,Anne Fusco,Lauren M. Cane,Naoko Takebe,Swapna S. Vemula,Nancy Bouvier,Boris C. Bastian,Gary K. Schwartz +17 more
TL;DR: Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients, indicating positive selection for the mutated allele.